A recent study reported complete remission in a myeloma patient who received CD19 CAR-T after myeloablative chemotherapy and autologous HSCT, even though only a minute fraction of myeloma cells was CD19-positive as assessed by FC6. This evidence concerns the gene CD19 and plasma cell myeloma.